Furthermore, as papillary thyroid carcinoma cells broadly expressed DR4 and DR5 on their surface, TRAIL is considered as a promising drug for treatment of PTC [9, 10, 11]. Here, TNFRSF10A is linked to differentiated thyroid carcinoma.